Previous studies have indicated that Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer [33]. The gene discussed is IL17A; the disease is neoplasm.